Mortality in Advanced Chronic Obstructive Pulmonary Disease and Heart Failure Following Cardiopulmonary Rehabilitation
Overview
Affiliations
Methods And Results: In this secondary analysis of a randomized controlled trial comparing two CR methods in severe COPD and HF, 90 (COPD = 63, HF = 27) male veterans, mean age 66 ± 9.24 years, 79% Caucasian, and body mass index 31 kg/m, were followed for 12 months after CR. The COPD group had greater functional decline than the HF group (6MWD, p = .006). Dyspnea was lower ( p = .001) and QoL higher ( p = .006) in the HF group. Mean NT-proBNP was higher in the HF group at all time points. FEV improved over 12 months in both groups ( p = .01). Mortality was 8.9%, 16.7%, and 37.8% at 12, 24, and 60 months, respectively. One-year predictors of mortality were baseline total steps (<3,000/day), 6MWD (<229 meters), and NT-proBNP level (>2,000 mg/pg).
Conclusions: In very severe COPD and HF, risks of mortality over 12 months can predict patients unlikely to benefit from CR and should be considered at initial referral.
Buttery S, Williams P, Alghamdi S, Philip K, Perkins A, Kallis C Eur Respir Rev. 2023; 32(170).
PMID: 37993126 PMC: 10663939. DOI: 10.1183/16000617.0134-2023.
Polhemus A, Delgado-Ortiz L, Brittain G, Chynkiamis N, Salis F, Gassner H NPJ Digit Med. 2021; 4(1):149.
PMID: 34650191 PMC: 8516969. DOI: 10.1038/s41746-021-00513-5.
Burge A, Cox N, Abramson M, Holland A Cochrane Database Syst Rev. 2020; 4:CD012626.
PMID: 32297320 PMC: 7160071. DOI: 10.1002/14651858.CD012626.pub2.